Odonate Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Tang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure12.3yrs
CEO ownershipn/a
Management average tenure8.8yrs
Board average tenure7.8yrs

Recent management updates

Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares

Jan 07
Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares

Recent updates

Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky

Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky

Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky

Jun 09
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky

We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate

Mar 09
We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate

Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares

Jan 07
Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares

Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?

Dec 09
Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Kevin Tang's remuneration changed compared to Odonate's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$119m

Mar 31 2021n/an/a

-US$130m

Dec 31 2020US$1US$1

-US$126m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$118m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$1US$1

-US$112m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$110m

Mar 31 2019n/an/a

-US$101m

Dec 31 2018US$1US$1

-US$89m

Compensation vs Market: Insufficient data to establish whether Kevin's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Kevin's compensation with company performance.


CEO

Kevin Tang (57 yo)

12.3yrs

Tenure

US$1

Compensation

Mr. Kevin C. Tang is Independent Director of Aurinia Pharmaceuticals Inc. from September 2024 & serves as its Independent Chairman. Mr. Tang serves as Director at Tetraphase Pharmaceuticals, Inc. since Jul...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Tang
Chairman & CEO12.3yrsUS$1.00no data
Michael Hearne
CFO & Principal Accounting Officer6.5yrsUS$572.17kno data
Ryan Cole
Senior Vice President of Operationsno datano datano data
Steven Pfeiffer
Senior Vice President of Technical Operations8.8yrsno datano data

8.8yrs

Average Tenure

57yo

Average Age

Experienced Management: ODTC's management team is seasoned and experienced (8.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Tang
Chairman & CEO12.3yrsUS$1.00no data
Laura Douglass
Independent Director6.4yrsUS$249.44kno data
Aaron Davis
Independent Director8.4yrsno datano data
Craig Johnson
Independent Director7.8yrsUS$274.44kno data
Robert Rosen
Director7.8yrsUS$249.44kno data

7.8yrs

Average Tenure

59yo

Average Age

Experienced Board: ODTC's board of directors are considered experienced (7.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/04 10:21
End of Day Share Price 2025/02/04 00:00
Earnings2021/09/30
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Odonate, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dana FlandersGoldman Sachs
Michael YeeJefferies LLC
Eric SchmidtTD Cowen